The funding has been awarded by its existing investors along with Forbion Capital Partners, Credit Agricole Private Equity and Vesalius BioCapital.
The company has progressed its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.
In the preclinical studies, AMA0076 showed reduction in intraocular pressure (IOP).